Boston Scientific has been granted a new technology add-on payment (NTPA) for its Eluvia drug-eluting vascular stent system from the Centers for Medicare & Medicaid Services. Under the Inpatient Prospective Payment System (IPPS), CMS pays for a patient’s inpatient hospital stay under one bundled payment, which covers all costs for

  Diagnostics manufacturers with government approval to test for the coronavirus strain COVID-19 are promising millions of tests kits to be produced weekly by the end of March and be commercially available. The Advanced Medical Technology Association (AdvaMed) said at least seven diagnostic companies have now received “emergency use authorization”

  Dear Vein Therapy News clients: The health and safety of our clients and employees is our highest priority. In normal times, we would see you at medical conferences and site visits. Because of the danger of contracting or spreading the coronavirus disease COVID-19, many of us will not be

    The U.S Food and Drug Administration has approved Boston Scientific’s VICI Venous Stent System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.

A December study in The Journal of the American Heart Association by Konstantinos Katsanos, MD, of Rion, Greece, et al, reported a higher risk of death after balloons and stents used to open vessels in the legs were coated with an anti-inflammatory chemo agent called paclitaxel. “Further investigations are urgently

After a year of holding the option to acquire Millipede, Boston Scientific decided to do it a year before the option ran out. When the pair signed the agreement last January, Boston Scientific paid $90 million for a portion of the mitral regurgitation startup’s shares. Now, Boston Scientific is spending $325 million

Now that everyone has said yes, Boston Scientific has gone to the banks to sign a number of new lending agreements, including a large credit facility it could use to finance its $4.2 billion acquisition offer for British medical device maker BTG plc. The information, which came from recently posted

Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals. Under the terms of the transaction, holders of BTG’s

    Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals. Under the terms of the transaction, holders